Uterine leiomyoma therapeutic - Eli Lilly
Latest Information Update: 09 Feb 2011
At a glance
- Originator Eli Lilly
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Uterine leiomyoma
Most Recent Events
- 24 Jan 2011 Discontinued - Phase-I for Uterine leiomyoma (unspecified route)
- 18 Oct 2010 Phase-I clinical trials in Uterine leiomyoma (unspecified route)